Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial

Arthritis and Rheumatism

Volumn 63, Issue 3, 2011, Pages 622-632

  Greenwald, Maria W ^a   Shergy, William J ^b   Kaine, Jeffrey L ^c   Sweetser, Marianne T ^d   Gilder, Kye ^d   Linnik, Matthew D ^d  

^a Desert Medical Advances   (United States)

^b Rheumatology Associates   (United States)

^c Sarasota Arthritis Research Center   (United States)

^d BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ADALIMUMAB; AZATHIOPRINE; COLESTYRAMINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RITUXIMAB;

ADULT; ARTHRALGIA; ARTICLE; CORONARY ARTERY OBSTRUCTION; DIZZINESS; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG USE; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; MYCOSIS; NAUSEA; OPPORTUNISTIC INFECTION; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINUSITIS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; PLACEBOS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79953718761     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30194     Document Type: Article

References (25)

1. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2009;68:1105-12.
2. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-93. (Pubitemid 32162981)
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
4. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. (Pubitemid 36091645)
5. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005;353: 1114-23. (Pubitemid 41317434)
6. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
7. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [published erratum appears in Ann Rheum Dis 2009;68:296]. Ann Rheum Dis 2008;67:1516-23.
8. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63. (Pubitemid 38198818)
9. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9. (Pubitemid 29063266)
10. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al, for the 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-9. (Pubitemid 38608062)
11. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006;54:2807-16. (Pubitemid 44497759)
12. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, doseranging trial. Arthritis Rheum 2006;54:1390-400.
13. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
14. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders [SERENE]). Ann Rheum Dis 2010;69:1629-35.
15. Genovese MC, Breedveld FC, Emery P, Cohen S, Keystone E, Matteson EL, et al. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:1894-7.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
17. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
18. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
19. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40. (Pubitemid 26036375)
20. Genovese MC, Breedveld FC, Emery P, Cohen S, Keystone E, Matteson EL, et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:1894-7.
21. Van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67.
22. Van Vollenhoven R, Emery P, Bingham C, Keystone E, Fleischmann R, Furst D, et al. Long-term safety of rituximab: follow-up of the RA clinical trials and re-treatment population [abstract]. Ann Rheum Dis 2009;68 Suppl 3:76.
23. Blank N, Max R, Schiller M, Briem S, Lorenz HM. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48:440-1.
24. Koumakis E, Wipff J, Avouac J, Kahan A, Allanore Y. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-α-blocking agents. J Rheumatol 2009;36:2125-6.
25. Loveless J, Olech E, Pritchard CH, Chai A, Kelman A, Klearman M. An open-label, prospective study (SUNDIAL) of the safety of rituximab in combination with disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis (SUNDIAL) [abstract]. Arthritis Rheum 2009;60 Suppl:S619.